Medications for Opioid Use Disorder (MOUD) Treatment in the Fentanyl Era: Patient, Provider, and System-Level Challenges

Background: Medications for Opioid Use Disorder (MOUD) have historically been the cornerstone of evidence-based treatment for opioid use disorder (OUD). However, the widespread proliferation of illicit fentanyl has introduced unprecedented challenges that threaten the effectiveness of traditional MOUD approaches. Objective: This paper examines the multifaceted barriers to MOUD implementation and effectiveness in the context of widespread fentanyl use, organized across patient, provider, and system levels. Methods: This paper synthesizes current literature on fentanyl-related challenges to MOUD delivery, focusing on precipitated withdrawal, pharmacological complications, patient perceptions, and healthcare system barriers. Key insights: Fentanyl's unique pharmacokinetic properties- including high lipophilicity, prolonged tissue accumulation, and variable elimination rates - fundamentally disrupt standard buprenorphine induction protocols. These pharmacological challenges cascade into patient-level barriers including fear of precipitated withdrawal, treatment avoidance, and premature dropout. Provider-level barriers include clinical uncertainty, inadequate training on fentanyl-specific protocols, and challenges with individualized dosing. System-level barriers encompass regulatory constraints, access limitations, and lack of integration between emergency, inpatient, and outpatient care settings. Conclusion: The fentanyl era has exposed critical gaps in MOUD delivery that span multiple levels of the healthcare system. Understanding these interconnected barriers is essential for developing targeted interventions and policy reforms. Future research should focus on fentanyl pharmacokinetics, optimized induction protocols, and MOUD efficacy in poly-substance use contexts.